Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS
Employer ID Number) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 23, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved the Company’s 2025 Equity Incentive Plan (the “2025 Plan”). The board of directors of the Company (the “Board”) had previously approved the 2025 Plan on April 30, 2025, subject to stockholder approval, and the 2025 Plan became effective upon such stockholder approval.
The 2025 Plan was summarized in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 12, 2025 (the “Proxy Statement”) under the heading “Proposal 5: Approval of the 2025 Equity Incentive Plan” and reflected in Annex C to the Proxy Statement, which description is incorporated herein by reference.
The foregoing description of the 2025 Plan is not complete and is qualified in its entirety by reference to the full text of the 2025 Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, the Company’s stockholders voted on the five proposals listed below. The proposals are described in detail in the Proxy Statement. The final results for the votes regarding each proposal are set forth below.
1. The stockholders elected the following individuals to serve on the Board until the annual meeting of shareholders to be held in 2026 and until their respective successors shall have been duly elected and qualified. The tabulation of votes with respect to the election of such directors was as follows:
| For | Withhold | Broker Non-Votes | ||||
| Jerome D. Jabbour | 5,622,949 | 68,739 | 1,808,948 | |||
| Evelyn D’An | 5,651,128 | 40,560 | 1,808,948 | |||
| Keith Murphy | 5,649,586 | 42,102 | 1,808,948 | |||
| Edward Neugeboren | 5,649,772 | 41,916 | 1,808,948 | |||
| Robin L. Smith | 5,651,653 | 40,035 | 1,808,948 |
2. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The tabulation of votes with respect to this proposal was as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 5,562,307 | 107,913 | 21,468 | 1,808,948 |
3. The stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended (the “Charter”), to effect up to two reverse stock splits of its common stock having an aggregate ratio in the range of 1-for-2 to 1-for-199 over a period of two years, with such reverse stock splits to be effected at such ratios, times and dates, if at all, as determined by the Board in its sole discretion. The tabulation of votes with respect to this proposal was as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 6,937,568 | 542,658 | 20,410 | N/A |
4. The stockholders approved an amendment to the Charter to increase the number of authorized shares of common stock from 250,000,000 to 500,000,000 and to make a corresponding change to the number of authorized shares of capital stock. The tabulation of votes with respect to this proposal was as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 6,913,714 | 566,405 | 20,517 | N/A |
5. The stockholders approved the 2025 Plan. The tabulation of votes with respect to this proposal was as follows:
| For | Against | Abstain | Broker Non-Votes | |||
| 5,391,325 | 278,413 | 21,950 | 1,808,948 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 10.1 | Matinas BioPharma Holdings, Inc. 2025 Equity Incentive Plan | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MATINAS BIOPHARMA HOLDINGS, INC. | ||
| Dated: June 23, 2025 | By: | /s/ Jerome D. Jabbour |
| Name: | Jerome D. Jabbour | |
| Title: | Chief Executive Officer | |